These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 126969)

  • 1. The inactivator of the first component of human complement (C1INA): the complex formation with plasmin.
    Nagaki K; Hashimoto C; Inai S
    Int Arch Allergy Appl Immunol; 1976; 50(1):1-13. PubMed ID: 126969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivator of the first component of human complement (C1INA). Enhancement of C1INA activity against C1s by acidic mucopolysaccharides.
    Nagaki K; Inai S
    Int Arch Allergy Appl Immunol; 1976; 50(2):172-80. PubMed ID: 128530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.
    Harpel PC; Cooper NR
    J Clin Invest; 1975 Mar; 55(3):593-604. PubMed ID: 123251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The inactivator of the first component of human complement (C1INA). The complex formation with the activated first component of human complement (C1) or with its subcomponents.
    Nagaki K; Iida K; Inai S
    Int Arch Allergy Appl Immunol; 1974; 46(6):935-48. PubMed ID: 4210434
    [No Abstract]   [Full Text] [Related]  

  • 5. C1 inactivator inhibition by plasmin.
    Harpel PC
    J Clin Invest; 1970 Mar; 49(3):568-75. PubMed ID: 4244455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on the purification and characterization of human urinary plasminogen and plasmin.
    Chen HF; Nakabayashi M; Satoh K; Sakamoto S
    Thromb Haemost; 1980 Feb; 42(5):1536-47. PubMed ID: 6445089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The isolation and characterization of a ternary human plasmin B-chain-streptokinase-plasminogen complex.
    Summaria L; Boreisha I; Barlow GH; Robbins KC
    Thromb Haemost; 1987 Aug; 58(2):772-7. PubMed ID: 2960030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Streptokinase-dependent delayed activation of horse plasminogen.
    Marcum JA; Highsmith RF; Kline DL
    Biochim Biophys Acta; 1982 Dec; 709(1):19-27. PubMed ID: 6217838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma.
    Collen D
    Eur J Biochem; 1976 Oct; 69(1):209-16. PubMed ID: 136345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The structure and mechanism of activation of the first component of complement.
    Reid KB; Porter RR
    Contemp Top Mol Immunol; 1975; 4():1-22. PubMed ID: 1104255
    [No Abstract]   [Full Text] [Related]  

  • 11. Evidence that C1s participates in the alternative complement pathway.
    Volanakis JE; Schultz DR; Stroud RM
    Int Arch Allergy Appl Immunol; 1976; 50(1):68-80. PubMed ID: 1244208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha 2-plasmin inhibitor-plasmin complexes in synovial fluid.
    Inman RD; Harpel PC
    J Rheumatol; 1986 Jun; 13(3):535-7. PubMed ID: 2942685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of molecular forms of plasminogen and plasmin-inhibitor complexes in urokinase-activated human plasma.
    Müllertz S; Thorsen S; Sottrup-Jensen L
    Biochem J; 1984 Oct; 223(1):169-77. PubMed ID: 6208893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.
    Müllertz S
    Biochem J; 1974 Nov; 143(2):273-83. PubMed ID: 4282470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of an IgG fragment prepared with particulate plasmin to study the C1 binding and activation.
    Arlaud GJ; Meyer CM; Colomb MG
    FEBS Lett; 1976 Jul; 66(1):132-6. PubMed ID: 132372
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies on human plasma C1 inactivator-enzyme interactions. II. Structural features of an abnormal C1 inactivator from a kindred with hereditary angioneurotic edema.
    Harpel PC; Hugli TE; Cooper NR
    J Clin Invest; 1975 Mar; 55(3):605-11. PubMed ID: 123252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degradation of C1-inhibitor by plasmin: implications for the control of inflammatory processes.
    Wallace EM; Perkins SJ; Sim RB; Willis AC; Feighery C; Jackson J
    Mol Med; 1997 Jun; 3(6):385-96. PubMed ID: 9234243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further studies on the identification of the subcomponents of the first component of complement after affinity chromatography of human serum on IgG-sepharose.
    Taylor PA; Fink S; Bing DH; Painter RH
    J Immunol; 1977 May; 118(5):1722-7. PubMed ID: 858917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydrodynamic studies on the streptokinase complexes of human plasminogen, Val442-plasminogen, plasmin, and the plasmin-derived light (B) chain.
    Barlow GH; Summaria L; Robbins KC
    Biochemistry; 1984 May; 23(11):2384-7. PubMed ID: 6236844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The interaction of human alpha 1-antitrypsin with human plasmin].
    Sakurama S
    Hokkaido Igaku Zasshi; 1984 Jan; 59(1):48-58. PubMed ID: 6232193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.